SCHEMBL5780263

SCHEMBL5780263

COc1cc(OC)c2c3c(c(Cl)nc2c1)C(=O)c1cnccc1-3

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 1/20 0.42
PDE3A Q14432 1/20 0.42
KDM4E B2RXH2 3/20 0.41
CYP3A4 P08684 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ALDH1A1 P00352 2/20 0.41
CYP1A2 P05177 2/20 0.41
MAPT P10636 2/20 0.41
CASP1 P29466 2/20 0.41
PDGFRB P09619 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
PDGFRA P16234 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP2C19 P33261 1/20 0.41
HSD17B10 Q99714 1/20 0.41
FBP1 P09467 1/20 0.39
CDC25B P30305 1/20 0.39
CCNE2 O96020 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5781906 0.83 IDO1 (0.42) KDM4ECYP3A4ALDH1A1CYP1A2PDGFRB
SCHEMBL5778921 0.79 CCNE2 (0.46) KDM4ECYP3A4ALDH1A1CYP1A2PDGFRB
SCHEMBL5782287 0.78 TOP1 (0.46) PDE3BPDE3AKDM4ECYP3A4MEN1
SCHEMBL5782137 0.77 CDC25B (0.38) KDM4ECYP3A4MEN1KMT2AALDH1A1
SCHEMBL5781191 0.74 GRM4 (0.39) KDM4ECYP3A4MEN1KMT2AALDH1A1
SCHEMBL5782672 0.74 CDC25B (0.40) PDE3BPDE3AKDM4ECYP3A4MEN1
SCHEMBL5783025 0.69 CDC25B (0.42) KDM4ECYP3A4MAPTCASP1PDGFRB
SCHEMBL7265998 0.69 CCNE2 (0.41) KDM4ECYP3A4MEN1KMT2AALDH1A1
SCHEMBL5784477 0.69 CA12 (0.36) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL7820788 0.69 USP8 (0.42) KDM4EKMT2AALDH1A1CDK4CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1436293-B1 POLYCYCLIC COMPOUNDS HAVING ANTI-TUMOR ACTIVITY HOFFMANN LA ROCHE (CH) 2006-02-01 EP disclosed
EP-1436293-A1 POLYCYCLIC COMPOUNDS HAVING ANTI-TUMOR ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2004-07-14 EP disclosed
US-6680326-B2 ANTITUMOR AGENTS; ANTICANCER AGENTS HOFFMANN-LA ROCHE INC. 2004-01-20 US disclosed
US-20030073691-A1 Polycyclic compounds HOFFMANN-LA ROCHE INC. 2003-04-17 US disclosed
WO-2003031444-A1 POLYCYCLIC COMPOUNDS HAVING ANTI-TUMOR ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2003-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073691-A1 Polycyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, PKD1 PDE3B 4070/4885PDE3A 4092/4885KDM4E 1718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.